Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2916 + Chemo or Penpulimab in Solid Tumors
NCT06500091Phase 2Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2916 in soft tissue sarcoma (STS), melanoma, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
TQB2916
03
Conditions
soft tissue sarcoma (STS)melanoma
Beyond the preview
Go deeper on NCT06500091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500091.